Polar Capital Holdings PLC Zentalis Pharmaceuticals, Inc. Transaction History

Polar Capital Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $11.6 Million - $18.2 Million	-572,423 Reduced 60.25%	377,728 $8.18 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $10.4 Million - $30.3 Million	580,822 Added 157.26%	950,151 $26.7 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $9.93 Million - $12.6 Million	-148,383 Reduced 28.66%	369,329 $31 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $1.65 Million - $2.58 Million	35,154 Added 7.28%	517,712 $34.5 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $1.22 Million - $2.03 Million	32,558 Added 7.24%	482,558 $25.7 Million
Q1 2021 May 17, 2021	BUY	$35.69 - $52.72 $8.03 Million - $11.9 Million	225,000 Added 100.0%	450,000 $19.5 Million
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $7.13 Million - $13 Million	225,000 New	225,000 $11.7 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.